* Korro Bio Inc is expected to show no change in quarterly revenue when it reports results on November 8 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Korro Bio Inc is for a loss of $2.61 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Korro Bio Inc is $120.00, above its last closing price of $66.63.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -2.40 -2.39 -2.43 Missed -1.5
Mar. 31 2024 -2.49 -2.51 -2.44 Beat 2.8
Dec. 31 2023 -2.57 -2.36 -25.65 Missed -985.3
Jan. 1 0001 -16.50 -17.72 -15.50 Beat 12.6
Jun. -17.34 -17.76 -15.00 Beat 15.6
30 2023
Mar. 31 2023 -20.50 -21.02 -27.50 Missed -30.8
Dec. 31 2022 -28.50 -31.54 -24.50 Beat 22.3
Jan. 1 0001 -27.97 -28.46 -27.50 Beat 3.4
This summary was machine generated November 6 at 23:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。